Compare BGSI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | DYN |
|---|---|---|
| Founded | 1990 | 1984 |
| Country | Canada | United States |
| Employees | 13449 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | N/A | 2020 |
| Metric | BGSI | DYN |
|---|---|---|
| Price | $106.95 | $17.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $157.00 | $37.00 |
| AVG Volume (30 Days) | 40.1K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.07 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $231.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $94.77 | $8.25 |
| 52 Week High | $183.10 | $25.00 |
| Indicator | BGSI | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 49.27 |
| Support Level | $94.77 | $16.57 |
| Resistance Level | $123.83 | $19.52 |
| Average True Range (ATR) | 5.52 | 0.94 |
| MACD | 0.38 | -0.02 |
| Stochastic Oscillator | 36.68 | 59.29 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.